The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Wednesday, 11 May 2022. The Annual General Meeting was conducted by way of postal…
"Despite a turbulent environment, we are pleased that the first quarter of 2022 has continued in the same positive direction as we saw in 2021. Both sales and gross margin set new records…
On Wednesday May 11, at 09.00 CET, Devyser Diagnostics AB will host an online presentation of its Q1 2022 interim report (which will have been published earlier on May 11, at 08.00 CET).…
Devyser announces a strengthening of its commercial organization with the appointment of Theis Kipling as Chief Commercial Officer (CCO) with global responsibility for sales, marketing,…
Devyser´s annual report 2021 has today been published on the company´s website.
The report is available on: https://investors.devyser.com/en/reports-presentations
The financial year…
Another record quarter
"Devyser’s sales were also strong in the fourth quarter 2021, as well as in the other quarters of the year. We have continued to feel the impact of the pandemic,…
On Thursday February 24, at 09.00 CET, Devyser Diagnostics AB will host a conference call and an online presentation of its Q4 2021 interim report (which will have been published earlier…
Stockholm, February 7, 2022 - Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that the company has utilized an option to acquire all of the…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN…
Stockholm, 29 December, 2021
Carnegie Investment Bank AB (publ) (“Carnegie”) has undertaken stabilisation measures in Devyser Diagnostics AB (publ)’s (“Devyser” or the “Company”) shares…
